Professor Rebecca Fitzgerald wins the Jane Wardle prize

A huge congratulations are due to Professor Rebecca Fitzgerald after she was recently awarded the prestigious Jane Wardle Prevention and Early Diagnosis prize, which recognises individuals who have produced world-leading research in the field of prevention and early detection of cancer.

Rebecca, Professor of Cancer Prevention and Honorary Consultant in Gastroenterology, is passionate about detecting cancer earlier and has developed the innovative Cytosponge test, currently in national clinical trial. The Cytosponge can detect a pre-cancerous condition of the oesophagus known as Barrett’s oesophagus – a condition that can increase a person’s risk of developing oesophageal cancer. Rebecca said, “It is a great honour to receive this award which is also a tribute to my fantastic team members (past and present). Jane Wardle was a pioneer in a field which is only now being fully recognised as a vital part of reducing the mortality and morbidity from cancer.”

More information about her work can be found here:  https://www.mrc-cu.cam.ac.uk/research/rebecca-fitzgerald/clinical-studies/BEST3

What is Oesophago-Gastric Cancer?

Oesophageal cancer is cancer of the gullet and gastric cancer is cancer of the stomach. Combined, they are medically known as oesophago-gastric (OG) cancer. The oesophagus (more commonly known as the gullet or food pipe) is the long tube that carries food from the throat to the stomach. In Northern Ireland in 2016, a total of 226 people were diagnosed with oesophageal (gullet) cancer. In the same year, 214 people were newly diagnosed with gastric (stomach) cancer.

Latest News

Access all of our latest news, press releases, and newsletters in one place! Stay informed of new treatments, research and events.

BBC Look East report about the BEST3 trial of the Cytosponge
Ogcancerni

BBC Look East report about the BEST3 trial of the Cytosponge

A great clip about the Cytosponge with Professor Rebecca Fitzgerald and the BBC.

Continue Reading
Update to NICE guideline on Barrett’s oesophagus: ablative therapy
Ogcancerni

Update to NICE guideline on Barrett’s oesophagus: ablative therapy

An update from NICE, indicates their decision to update their guidance on Barrett’s ablative therapy CG106 after considering the evidence and consulting with experts. Information about the decision has been published on their website.If you have any queries about the update decision, please contact surveillance@nice.org.uk

Continue Reading
Clinical Trials with Cancer Research
Ogcancerni

Clinical Trials with Cancer Research

Clinical trials are an essential step towards getting new treatments and detection tests into the clinic. Liz Chipchase signed up for a clinical trial, unaware it would be a decision that would save her life. She took part in the BEST3 trial, which studies the effectiveness of the Cytosponge.  The Cytosponge, or ‘Pill on a...

Continue Reading